IMADEV 400mgÊ Price

Overview

Welcome to Dwaey, specifically on IMADEV 400mgÊ Tablets/Film-coated page.
This medicine contains an important and useful components, as it consists of Imatinib mesylate.
IMADEV 400mgÊ is available in the market in concentration 400mg/Tablet and in the form of Tablets/Film-coated.

DEVA HOLDING A.S is the producer of IMADEV 400mgÊ and it is imported from TURKEY, The most popular alternatives of IMADEV 400mgÊ are listed downward .

Mode Of Action

Imatinib, is a tyrosine kinase inhibitor that inhibits the BCR-ABL tyrosine kinase created by the Philadelphia chromosome abnormality in chronic myeloid leukaemia (CML). It blocks proliferation and induces apoptosis in BCR-ABL positive cell lines, as well as fresh leukaemic cells from Philadelphia chromosome positive CML. Imatinib also inhibits receptor kinases for platelet-derived growth factor (PDGF) and stem cell factor (SCF), c-kit, PDGF- and SCF-mediated cellular events.

Indication

• Chronic myeloid leukaemia
• Acute lymphoblastic leukaemia
• Myelodysplastic disease
• Hypereosinophilic syndrome
• Mastocytosis
• Dermatofibrosarcoma protuberans
• Malignant gastrointestinal stromal tumours

Precaution

Cardiac disease or increased risk for CHF. Monitor for signs of severe fluid retention. Monitor CBC regularly. Renal and hepatic impairment. Monitor LFTs. Pregnancy. Lactation: Imatinib and its active metabolite are excreted into human milk; advise a lactating woman not to breastfeed during treatment and for 1 month after last dose

Side Effects

• >10% Edema (53%)
• Neutropenia (Grade 3: 7-27%; Grade 4: 3-48%)
• Nausea (43%)
• Muscle cramps (35%)
• Musculoskeletal pain (34%)
• Thrombocytopenia (Grade 3: 1-31%; Grade 4: 1-34%)
• Rash (32%)
• Fatigue (31%)
• Diarrhea (30%)
• Headache (29%)
• Arthralgia (27%)
• Abd pain (23%)
• Myalgia (21%)
• Nasopharyngitis (19%)
• Hemorrhage (19%)
• Vomiting (15%)
• Dyspepsia (15%)
• Cough (13%)
• Dizziness (13%)
• URT infection (13%)
• Fever (12%)
• Weight gain (12%)
• Hepatotoxicity (6-12%)
• Insomnia (11%) 1-10% Flushing
• Palpitation
• Dry skin
• Erythema
• Metabolic hyperglycemia
• Stomatitis/mucositis
• Lymphopenia <1% Aplastic anemia
• Atrial fibrillation
• Avascular necrosis
• Cardiac failure
• Cardiogenic shock
• Embolism
• Eosinophilia Potentially Fatal: Hepatotoxicity
• cerebral oedema
• increased intracranial pressure
• papilloedema. Severe fluid retention resulting in pleural and pericardial effusion
• pulmonary oedema and ascites. Rarely
• GI perforation.

Contra indication

Hypersensitivity. Lactation.

Pregnancy and lactation

Pregnancy category: D

There is positive evidence of human fetal risk based on adverse reaction data from investigational or marketing experience or studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks.